


Ximelagatran

Chemical Properties

CAS No. :	192939-46-1
Formula:	C ₂₄ H ₃₅ N ₅ O ₅
Molecular Weight:	473.57
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Ximelagatran (H 376-95), a direct thrombin inhibitor, can be taken orally and acts solely by inhibiting the actions of thrombin. Ximelagatran is converted to the active agent melagatran in vivo.
Targets(IC50)	Thrombin
In vitro	Ximelagatran, an orally administered direct thrombin inhibitor, is currently being developed for both the prophylaxis and treatment of thromboembolism. Once ingested, it is rapidly absorbed and converted into its active metabolite, Melagatran, which acts as a reversible, active-site inhibitor targeting both free and clot-bound thrombin, showcasing stable and reproducible pharmacokinetic properties. Initial research indicates Ximelagatran's promising efficacy and safety profile in preventing venous thromboembolism following total knee or hip replacement surgeries[1].

Solubility Information

Solubility	DMSO: 55 mg/mL (116.14 mM), Sonication is recommended. H ₂ O: Insoluble (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.22 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1116 mL	10.5581 mL	21.1162 mL
5 mM	0.4223 mL	2.1116 mL	4.2232 mL
10 mM	0.2112 mL	1.0558 mL	2.1116 mL
50 mM	0.0422 mL	0.2112 mL	0.4223 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Francis CW, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. *N Engl J Med.* 2003 Oct 30;349(18):1703-12.

Lazo-Langner A, Rodger MA, Wells PS. Lessons from ximelagatran: issues for future studies evaluating new oral direct thrombin inhibitors for venous thromboembolism prophylaxis in orthopedic surgery. *Clin Appl Thromb Hemost.* 2009 May-Jun;15(3):316-26. doi: 10.1177/1076029608326166. Review. PubMed PMID: 19028773.

Testa L, Bhindi R, Agostoni P, Abbate A, Zoccai GG, van Gaal WJ. The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. *Expert Opin Drug Saf.* 2007 Jul;6(4):397-406. Review. PubMed PMID: 17688383.

Koscielny J, Kiesewetter H, Jörg I, Harenberg J. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis. *Clin Appl Thromb Hemost.* 2007 Jul;13(3):299-307. Review. PubMed PMID: 17636192.

Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. *Handb Exp Pharmacol.* 2010;(196):407-18. doi: 10.1007/978-3-642-00663-0_13. Review. PubMed PMID: 20020269.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481